( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57



*Chandran Stella Packiam, Robert Jothibai Margret and Vaidyanathapuram Kesavan Meenakshi


Hyperlipidemia is a disorder of lipid metabolism manifested by elevation of plasma concentrations of various lipid and lipoprotein fractions. It has been ranked as one of the greatest risk factors contributing to the prevalence and severity of coronary heart diseases. Hyperlipidemia is identified as dyslipidemia and it can also be described as elevated total cholesterol (TC) or triglycerides (TG), or low levels of high density lipoprotein cholesterol (HDL). People with high cholesterol have about twice the risk of coronary heart disease. Several risk factors of hyperlipidemia have been reported - age, sex, obesity, wrong diet, blood pressure, blood sugar, stress, smoking and environment. The present study was designed to explore the potential of the ethanol extract of Ascidia sydneiensis against Triton X-100 induced hyperlipidemic rats. Body weight, serum biochemical parameters - protein, albumin, globulin, SGPT, SGOT, ALP, serum lipid profile - Total cholesterol (TC), Triglycerides (TG), high density lipoprotein - cholesterol (HDL-C), very low density lipoprotein - cholesterol (VLDL-C), low density lipoprotein - cholesterol (LDL-C) and phospo lipids were analysed following standard procedures. Histopathological examinations of liver sections were also done. Administration of the extract at a dose of 50, 100 and 150 mg/kg b.w was compared with Triton induced hyperlipidemic control and standard drug Atorvastatin (100 mg/kg b.w). A significant decrease in body weight, serum enzyes - SGPT, SGOT, ALP, plasma lipid profile - TC, TG, VLDL-C, LDL-C, PL, faecal lipid profile - TL, TC, TG and an elevation in serum biochemical parameters - protein, albumin, globulin and plasma lipid profile - HDL-C were noted in the extract treated groups when compared to hyperlipidemic control. In the group treated with the highest dose of the extract all the biochemical parameters were brought back to normal level. The effective suppression Triton induced hyperlipidemia in rats on treatment with the extract suggests the potential protective role in coronary heart disease.

Keywords: Ascidia sydneiensis, Triton X-100, atorvastatin, hyperlipidemia, plasma lipid profile.

[Full Text Article]



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2021 Issue has been Published, Kindly check it on


    NOVEMBER Issue has been successfully launched on 1 November 2021.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )